AQST - Aquestive Therapeutics Inc

AQST - Aquestive Therapeutics Inc

https://www.aquestive.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA

Zacks Commentary • 1 week, 3 days ago • score: -0.06

Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.

Why Is Aquestive Therapeutics Stock Soaring Thursday? - Aquestive Therapeutics ( NASDAQ:AQST )

Benzinga • 1 week, 4 days ago

FDA skips advisory committee review for Aquestive's Anaphylm sublingual allergy film. The target action date for Anaphylm's approval is set for January 31, 2026. September's volatility catalysts are coming. Find out how to trade new inflation reports and fed signals here → The U.S.

Is Aquestive Therapeutics ( AQST ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 1 month ago • score: 0.33

Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Aquestive Therapeutics ( AQST ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.11

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +22.22% and -9.62%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.

52W High

$5.80

52W Low

$2.12

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.82

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-1.81

EV/Revenue (<3 favorable)

14.40

P/S (TTM) (<3 favorable)

14.86

P/B (<3 favorable)

N/A

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

4.39%

Institutions (25–75% balanced)

42.88%

Shares Outstanding

120,974,000

Float

94,927,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

As of 2025-06-30 (Overview)

Revenue (TTM)

44,132,000

Gross Profit (TTM)

26,962,000

EPS (TTM)

-0.69

Profit Margin (>10% good)

-1.47%

Operating Margin (TTM) (higher better)

-1.14%

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.50

Momentum

Bearish momentum

Value

0.3697

Previous

0.3557

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025